Status:
COMPLETED
Skin Adverse Reactions Occuring in Children Treated by Biotherapy for Chronic Inflammatory Disease
Lead Sponsor:
Centre Hospitalier Universitaire, Amiens
Conditions:
Biotherapy
Chronic Inflammatory Disease
Eligibility:
All Genders
Up to 18 years
Brief Summary
Biological treatments (BT) are commonly prescribed to treat chronic inflammatory diseases in children. Paradoxical reactions during treatment with a biological agent can be defined as the appearance o...
Eligibility Criteria
Inclusion
- Children under 18 years old
- Children treated by biotherapy among : Adalimumab, Golimumab, Infliximab, Ustekinumab, Etanercept, Tocilizumab, Canakinumab, Anakinra, Abatacept.
- Children treated for a chronic inflammatory disease (rheumatologic, gastro-enterologic, dermatologic and ophthalmologic)
- Children treated in the CHU of Amiens
- Parental consent signed
Exclusion
- Age \> 18 ans
Key Trial Info
Start Date :
March 12 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2020
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT04327752
Start Date
March 12 2020
End Date
October 1 2020
Last Update
July 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Amiens
Amiens, France, 80480